A New Breath Test May Help Identify Silicosis Risk Earlier
April 22, 2026Silicosis is a severe and progressive occupational lung disease caused by inhalation of respirable crystalline silica. One of the most dangerous modern sources of this exposure is artificial stone, also referred to as engineered stone or manufactured stone. Artificial stone contains at least 90% silica, with nano‑sized silica particles, while the remaining approximate 10% consists of other toxins and carcinogens known as volatile organic compounds (VOCs).
When artificial stone is cut, ground, or polished, extremely high concentrations of respirable silica dust are released into the air. Over time, inhalation of this dust leads to chronic inflammation, progressive scarring, and permanent damage deep within the lungs. Once this damage develops, it cannot be reversed.
Medical care for silicosis currently focuses on managing symptoms and slowing disease progression. At the same time, scientific researchers continue to study whether stem cell–based approaches may one day address the biological processes that drive inflammation and fibrosis in silica‑damaged lungs.
Why Stem Cells Are Being Studied in Silicosis Research
Silicosis develops when respirable crystalline silica particles lodge in lung tissue and trigger sustained immune responses. These responses activate biological pathways that result in:
- Persistent lung inflammation
- Excessive formation of fibrotic scar tissue
- Disruption of normal immune regulation within the respiratory system
Current therapies do not eliminate fibrosis once it forms. Stem cells are being studied because they regulate immune signaling, influence inflammatory pathways, and support tissue maintenance mechanisms, making them a focus of ongoing laboratory and early clinical research.
Categories of Stem Cells Under Investigation
Mesenchymal Stem Cells (MSCs)
Adult stem cells with immunomodulatory and anti‑inflammatory properties that are being examined in early‑stage lung disease research.
Airway Basal Stem Cells
Naturally occurring cells in the respiratory tract that contribute to maintaining airway lining cells and are being studied for their response to lung injury.
Induced Pluripotent Stem Cells (iPSCs)
Reprogrammed adult cells with regenerative potential, currently under evaluation for safety and long‑term behavior.
Barriers to Clinical Use
Stem cell therapies for silicosis are not approved for clinical treatment. Ongoing research continues to address challenges such as:
- Consistent production of high‑quality cells
- Effective delivery into fibrotic lung tissue
- Long‑term safety evaluation
- Large‑scale, controlled clinical research
What This Research Means for Individuals with Silicosis
Stem cell therapies remain investigational and are not available as treatment options. However, ongoing research continues to clarify how respirable crystalline silica from artificial stone causes lung injury and how future medical approaches may better address inflammation and fibrosis.
Frequently Asked Questions
Are stem cell therapies currently used to treat silicosis?
No. Stem cell therapies are not approved for treating silicosis and remain in the research phase.
Can stem cells reverse lung scarring caused by silica?
Lung fibrosis caused by silica exposure is permanent. Research focuses on limiting inflammation and slowing progression.
Why does artificial stone pose such a serious health risk?
Artificial stone contains at least 90% silica with nano‑sized particles, along with VOCs. Fabrication activities release extremely high levels of respirable crystalline silica dust.
